Can a cholesterol drug help fight lung cancer? new study explores combo therapy
NCT ID NCT05553834
First seen Feb 02, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests whether adding a cholesterol-lowering drug (alirocumab) to an immunotherapy (cemiplimab) can shrink tumors in people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. About 60 participants will receive the combination to see if it improves response rates. The goal is to find a new treatment option for those who have run out of effective therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27705, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.